BridgeMD
Effects of combined diuretic therapy on exercise capacity, alveolar-capillary diffusion and maintenance of euvolemia in chronic congestive heart failure, diuretic therapy compared with loop diuretics and potassium-sparing diuretics
EU CTIS ID: 2024-519565-21-01
What this study is testing
To compare two different treatment strategies (control arm treated with loop diuretic and potassium sparing and experimental arm that will combine such therapy with acetazolamide and free-dose metolazone) in patients with chronic heart failure.
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- written informed consent signed
- Age: 18-80
- Patients with chronic heart failure (at reduced or preserved ejection fraction)
- Patients discharged after hospitalization for acute heart failure (at least second episode of decompensation in the past 12 months)
- Patients being treated with loop diuretics at the same or higher dosage of furosemide 40 mg (or equivalent) at the time of admission
You likely can't join if
- age <18 years or >85 years
- patients with severe aortic stenosis
- patients with severe renal failure (eGFR<20 ml/min/1.73m2 according to CockroftGault)
- patients with severe hyponatremia
- Medical therapy for heart failure optimized during hospitalization
- Documented current pregnancy and lactating status in women of childbearing potential
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.